secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0000950170-25-043497
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology reports 75.5% complete response rate in Phase 3 bladder cancer trial; median DOR >28 months
--------------------------------------------------------------------------------

- 83 of 110 patients (75.5%) achieved complete response at any time in BOND-003 for BCG-unresponsive NMIBC with CIS.
- Median duration of response not reached but exceeds 28 months; 46% in CR at 12 months.
- No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all expected treatments.
- Translational data show no systemic exposure, eliminating need for close contact precautions post-treatment.
- Data presented as late-breaking abstract at 40th Annual EAU Congress in Madrid.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/0000950170-25-043497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/ck0001991792-20250324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-043497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer